BCWORLD PHARM. Co. vs Eli Lilly and: Fair Value & Quality
Both stocks run through our valuation models. Here is how BCWORLD PHARM. Co. (200780) and Eli Lilly and (LLY) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees BCWORLD PHARM. Co. as the less overvalued of the two: BCWORLD PHARM. Co. trades at KRW 3,215 versus a fair value of KRW 1,822 (-43%), while Eli Lilly and trades at $1,186 versus $397 (-67%).
BCWORLD PHARM. Co.
200780.KQ · KRW · Health Care
-43%
upside to fair value
overvalued
PriceKRW 3,215
Fair ValueKRW 1,822
Quality34/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,186
Fair Value$397
Quality69/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
BCWORLD PHARM. Co.Eli Lilly and
Valuation
—P/E (TTM)42.2×
—P/S (TTM)14.67×
—P/B39.94×
0.7×EV/EBITDA30.2×
—PEG1.54×
3.2%Dividend yield0.5%
KRW 100Dividend per share$6.23
Profitability
15%Net margin35%
9%Operating margin49%
10%Return on equity107%
5%Return on assets21%
Growth
25%Revenue growth (YoY)56%
1.4%Avg. growth/yr (3Y)31.7%
5.9%Avg. growth/yr (5Y)21.6%
Balance & size
0.20×Debt / equity1.54×
$23MMarket cap$1.1T
mixedGrowth qualitymixed
Eli Lilly and leads: 3 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
BCWORLD PHARM. Co.of which business quality 29 · market factors 27Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
13
85
Quality GrowthAre margins and returns improving?
50
86
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
94
15
Low VolatilityCalm price path (market factor)
71
73
MomentumPrice trend over the last 3–12 months (market factor)
8
78
52W MomentumDistance to the 52-week high (market factor)
11
92
Net IssuanceBuybacks instead of dilution
6
93
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
BCWORLD PHARM. Co.
DCF ModelsKRW 1,796
Earnings-BasedKRW 1,159
MultiplesKRW 2,527
Asset-BasedKRW 4,673
Growth DCFKRW 1,724
Economic ProfitKRW 1,159
9 of 13 models see the stock below the current price.
Eli Lilly and
DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
BCWORLD PHARM. Co.
Bear KRW 926Fair Value KRW 1,822Bull KRW 3,297
KRW 3,215 = current price (white tick)
Eli Lilly and
Bear $222Fair Value $397Bull $582
$1,186 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
BCWORLD PHARM. Co. · Health Care
Quality score34 · bottom 25%
Fair value upside-43% · below median
Eli Lilly and · Health Care
Quality score69 · Top 25%
Fair value upside-67% · bottom 25%
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees BCWORLD PHARM. Co. as the less overvalued of the two: BCWORLD PHARM. Co. trades at KRW 3,215 versus a fair value of KRW 1,822 (-43%), while Eli Lilly and trades at $1,186 versus $397 (-67%).
Eli Lilly and has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
